Dechra's US availability launch of Laverdia gives veterinary teams an FDA-approved oral option for dogs diagnosed with lymphoma, a development that may broaden the set of practical conversations that can follow a difficult diagnosis.

Announced on 23 September, Laverdia contains verdinexor and is described by Dechra as the first and only FDA-approved oral treatment for dogs with lymphoma. The tablets are intended for administration at home and can be used immediately after diagnosis, while owners consider multi-agent chemotherapy, after relapse, or where multi-agent chemotherapy is not the preferred course. Dechra offers the treatment in multiple SKUs to dose dogs across weight ranges.

The commercial relevance lies in a gap between diagnosis and access to treatment. Dechra cites estimates that only about 20% of dogs with lymphoma receive chemotherapy. An oral, at-home treatment does not remove the need for clinical judgment, monitoring or specialist care, but it gives primary-care teams and owners another route to act while treatment plans are being considered.

That distinction matters for practice economics as well as patient care. Cancer medicine in companion animals often combines clinical complexity with time-sensitive choices, referral considerations and owner budgets. A treatment that veterinarians can discuss from day one may help practices keep more of the initial decision-making within a coordinated care pathway, even when an owner ultimately chooses a different option.

The source describes Laverdia as a targeted therapy intended to help slow disease progression while generally sparing healthy cells, with demonstrated efficacy in both B-cell and T-cell lymphoma. It also sets out substantial safety information: the medicine can cause adverse reactions including anorexia, vomiting, diarrhoea, dehydration and blood or chemistry abnormalities, and dogs require careful monitoring. It is not for use in pregnant, lactating or breeding dogs, and handlers must follow the prescribed precautions.

The launch therefore should be read as an expansion of therapeutic choice, not a substitute for a full oncology assessment. But by pairing an approved oral medicine with home administration, Dechra is addressing a practical pressure point in a growing, high-touch segment of companion-animal care.

For more information: Dechra